Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GI and Health-related Quality of Life After Switch From MMF to Myfortic in Liver Transplant Recipients
2005-002234-35Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mycophenolate sodium in liver transplant recipient (LTR), sponsored by Novartis. Primary endpoints: Change in GI and HRQL questionnaire responses after conversion and Proportion of patients with GI symptoms under MMF. Started Jan 2006; status: completed.
02
Drugs
mycophenolate sodium
03
Conditions
liver transplant recipient (LTR)
Beyond the preview
Go deeper on 2005-002234-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002234-35.